492 EMBOLIC STROKE OF UNDETERMINED SOURCE: ROLE OF IMPLANTABLE LOOP RECORDER IN ASYMPTOMATIC ATRIAL FIBRILLATION DETECTION AND SECONDARY PREVENTION OF NEW EMBOLIC EVENTS

نویسندگان

چکیده

Abstract Background and Aims AF (Atrial Fibrillation) is the most important cause of Embolic Stroke Undetermined Source (ESUS). Implantable Loop Recorder (ILR) demonstrated highest sensitivity for detecting post-stroke asymptomatic AF. This register was created to assess prevalence episodes in patients after ESUS verify possible benefits on clinical outcomes such as TIA or stroke recurrence death using ILR. Methods 278 admitted Unit “Città della Salute e Scienza” hospital Torino between 2011 2019, underwent ILR implantation if they had at least one risk factor including obesity, hyperthyroidism, atrial enlargement transthoracic echocardiography, severe mitral valve disease, CHADS-VASc score ≥ 4, age > 70 years old diabetes. The control group composed 165 other departments same diagnosed with ESUS, not implanted We used propensity matching select 132 from each (matching age, sex, CHADS-VASc, HAS-BLED baseline characteristics). Risk protective factors were estimated (deaths recurrence) evaluated logistic regression univariate multivariate analyses. Results detection rate longer than 5 minutes significantly higher (41.7% vs 15.9%, p<0.001). On analysis, we found a trend towards role composite outcome mortality (OR 0.52, CI 0.26–1.04, p 0.06). terms deaths 0.4, 0.17–0.94, 0.03) ischemic event recurrences 0.41, 0.19–0.87, 0.02). Age consistently identified all outcomes. Conclusion In AF, are 41.7% cases thanks Our study that policy also gives benefit death, although limited size population presence selection bias may limit generalisation our results.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Embolic Stroke of Undetermined Source

In 2014, the clinical construct of “embolic stroke of undetermined source” (ESUS) was introduced to identify patients with nonlacunar cryptogenic ischemic strokes in whom embolism was the likely stroke mechanism. It was hypothesized that anticoagulants might be more efficacious than antiplatelet agents for secondary stroke prevention in ESUS patients. At the time of the original publication, li...

متن کامل

High Incidence of Atrial Fibrillation After Embolic Stroke of Undetermined Source in Posterior Cerebral Artery Territory

BACKGROUND Subclinical atrial fibrillation is one possible cause of embolic stroke of undetermined source (ESUS). It remains to be elucidated if a specific infarction site has a predictive value for detecting subclinical atrial fibrillation. We aimed to investigate the predictive value of infarction site in patients with ESUS for the detection of atrial tachyarrhythmia (AT) using an insertable ...

متن کامل

Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.

BACKGROUND AND PURPOSE Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis. METHODS We randomized...

متن کامل

Association Between Troponin Levels and Embolic Stroke of Undetermined Source

BACKGROUND Our aim was to determine whether patients with embolic strokes of undetermined source (ESUS) have higher rates of elevated troponin than patients with noncardioembolic strokes. METHODS AND RESULTS CAESAR (The Cornell Acute Stroke Academic Registry) prospectively enrolled all adults with acute stroke from 2011 to 2014. Two neurologists used standard definitions to retrospectively as...

متن کامل

Embolic Stroke, Atrial Fibrillation, and Microbleeds

Patients with AF have a high risk of ischemic stroke, which can be dramatically reduced by oral anticoagulation with vitamin K antagonists (VKAs). I will look at our patient from different positions. First, the patient has paroxysmal AF. The type of AF (paroxysmal, persistent, or permanent) has only a minor impact on the stroke risk. All types of AF respond to oral anticoagulation with VKAs or ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: European Heart Journal Supplements

سال: 2022

ISSN: ['1520-765X', '1554-2815']

DOI: https://doi.org/10.1093/eurheartjsupp/suac121.071